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Abstract 
Objectives: To study the association between serum C-
reactive protein (CRP) and arteriovenous fistula (AVF) 
failure rate. 
Patients and Methods: This case control study 
Department of Vascular Surgery Combined Military 
Hospital Lahore and Peshawar between January 2015 and 
March 2016. Total 126 consecutive patients who had serum 
CRP checked preoperatively and underwent AVF procedure 
were included. Patients were divided into Case (with raised 
CRP) and Control (Normal CRP) groups. Data regarding 
serum CRP level were recorded and analysed to evaluate the 
impact of preoperative CRP levels on AVF failure rates. 
Results: The AVF failure rate was significantly high 
(53.2%) in case group as compared to control group 
(14.5%). Age, gender, diabetes and hypertension did not 
show statistically significant difference between the two 
groups. 
Conclusion: Raised level of CRP is related to significantly 
higher AVF maturation failure rate. Therefore, it is 
recommended to check CRP levels preoperatively to identify 
those patients who can be at higher risk of fistula failure. 
Keywords:  Arteriovenous fistula, Association, C-reactive 
protein 
Introduction 
The morbidity and mortality in end stage renal disease 
(ESRD) patients has been decreased with recent advances in 
medicine and improvement in general health measures in 
spite of increased prevalence of the disease.1,2 The major 
role in improving the survival of ESRD patients has been 
played by hemodialysis (HD) as renal replacement therapy.3 
HD needs vascular access and the best way of getting this 
vascular access is by creating an AVF.4  AVF can be a good 
option due to decrease rate of complication and increase 
durability. But increase tendency of vasospasm in small 
vessels decreases its effectiveness and can lead to both early 
and late failures. In a clinical setting, early failure of AV 
fistula can be defined as fistula that does not have any 
effective development for dialysis or after initiation of 
dialysis failure occurs within 3 months. Late failure is 
defined as malfunction after successful use. Definition of 
adequate AV fistula based on rate of blood flow, diameter of 
fistula and its distance from skin.   Early failure or failure to 
maturity is main issue in about 23% to 46 % of all AV 
fistulas.  
AVF has to be functionally mature before its use. Many 
factors like advancing age, female gender, smoking, 
diabetes, hypertension, hyperlipidemia, 
hyperparathyroidism, vascular disease, technical errors, high 
hemoglobin level, thrombophilia, low albumin levels, 
malnutrition and inflammatory biomarkers affect this 
maturation process and can result in AVF failure.5-10  
In vessels reduction in blood flow and oscillatory shear 
stress results in increased levels of inflammatory and pro-
coagulant substances.5 CRP that is an important 
Inflammatory marker, not only has a role in prediction of 
development of cardio vascular disease in patients 
undergoing HD. But its importance regarding development 
of vascular stenosis and thrombosis through the process of 
vascular intimal hyperplasia is also under discussion.5 Fewer 
studies have been conducted with conflicting evidence to 
evaluate the effects of inflammatory biomarkers on AVF 
maturation11,12. We designed this study to evaluate 
relationship between preoperative raised CRP and AVF 
failure in ESRD patients. 
Patients and Methods 
All patients between January 2015 and March 2016, 
reporting to Vascular Surgery Clinic in Combined Military 
Hospital Lahore and Peshawar for AVF creation, were 
consecutively included in this study. Patients with 
uncontrolled diabetes (fasting blood sugar of more than 
126mg/dl) and uncontrolled hypertension (blood pressure of 
more than 160/90 mmHg) were excluded. Serum CRP of all 
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patients was checked in the hospital laboratory using 
Enzyme-Linked Immuno-Sorbent Assay (ELISA) method. 
CRP level more than 10mg/L was considered as positive 
value. Based on the serum CRP results, patients were 
assigned into two groups. Group A(Control) had all patients 
with normal CRP and Group B (Case) has patients with 
raised CRP. Other procedure related complications were 
also recorded. 
All patients underwent AVF procedure by a Consultant 
Vascular Surgeon who had a minimum of five years of 
experience of doing such procedure under local anaesthesia. 
In order to remove the operator bias, the operating surgeon 
was kept unaware about the CRP status of the patient before 
and during the procedure. Patients were given oral 
antibiotics and analgesia on discharge. They were provided 
written instructions about hand and forearm exercises and 
general care of the AVF. Patients were regularly followed 
up in clinic at 2 weeks, 4 weeks, 2 months and 3 months. A 
functionally mature AVF is defined as per Kidney Disease 
Outcome Quality Initiative (KDOQI) guidelines as one that 
can be easily cannulated and has at least six successful 
consecutive dialysis sessions.13 The failure rate and 
association with CRP was recorded. 
The data was analyzed using Statistical Package for Social 
Sciences (SPSS) version 20. The numerical outcomes e.g. 
age was calculated as mean and standard deviation. Gender 
was recorded as frequency and percentage. Chi Square test 
was applied to assess the association between failure of 
fistula and qualitative variables like diabetes, hypertension 
and CRP. Independent t-test was applied to see the 
association between failure of fistula and quantitative 
variables like age. Logistic regression analysis was also 
done to assess the effect of age, gender, diabetes mellitus, 
hypertension and CRP on fistula failure rates. The results 
were considered statistically significant if the p value was 
found to be less than or equal to 0.05. 
 
Results 
Total 126 patients fulfilling the inclusion criteria were 
included in this study. The age range was 31 years - 64 years 
with mean age of 37.5±8.4 years. Out of 126 cases, 99 
(78.5%) were males and 27 (21.4%) were females. Male to 
female ratio was 3.6:1. There were two groups: Group A 
(Control) had 62 patients with normal CRP and Group B 
(Case) had 62 patients with raised CRP. Among factors like, 
age (p value 0.754), gender (p value 0.867), diabetes (p 
value 0.812) and hypertension (p value 0.835); there was no 
statistically significant difference in the two groups (Table 
1).  
In Control group, 53 fistulae matured however in Case 
group only 29 AVF became functionally mature. Hence the 
failure rate was 14.5% in patients with normal CRP as 
compared to 53.2% in patients with raised CRP (Table 2). 
This difference between the two groups was statistically 
significant with a p value of 0.003. 
Table 1: Comparison of variables between control and 
case groups 
Variable 
 
Group A 
(Control) 
n =62 
Group B 
(Case) 
n =62 
p value 
 
Age(yrs) 
Mean±SD 
 
38.1 ± 9.3 
 
36.9 ± 7.8 
 
0.754 
Gender Male 
   No (%)  
 
47 (75.8) 
 
52 (83.8) 
 
0.867 
Diabetic 
  No (%) 
 
42 (67.7) 
 
39 (62.9) 
 
0.812 
Hypertensive 
   No (%) 
 
38 (61.2) 
 
35 (56.4) 
 
0.835 
 
Table 2: Distribution of CRP in Control and Case 
groups 
Group Category Number  Percentage 
Group A 
  N (62) 
Failed 09 14.5 
Mature 53 85.5 
Group B 
  N (62) 
Failed 33 53.2 
Mature 29 46.8 
 
Table 3: Logistic regression analysis showing effect of different 
variables on fistula failure 
Variable B SE p value 
Odd 
Ratio 
95% Confidence 
Interval 
Lower Upper 
Age 0.013 0.026 0.914 0.885 0.854 1.124 
Gender -0.294 0.526 0.794 0.726 0.384 1.754 
Diabetes -0.354 0.559 0.857 0.998 0.926 1.212 
Hypertension -0.261 0.591 0.932 0.869 0.442 1.954 
CRP 2.985 0.416 <0.002 21.254 5.316 67.214 
 
Logistic regression analysis of the variables was also done. 
The effect of age, gender, hypertension, diabetes mellitus 
and CRP was assessed on AVF failure. Only CRP had 
statistically significant effect on fistula failure rate with a p 
value of <0.002 (Table 3). 
 
Discussion 
HD in ESRD patients needs a vascular access. Vascular 
access can be achieved by a catheter insertion, arteriovenous 
graft or by creating a native AVF.2-4 AVF is used for HD 
once it is matured functionally within 4-6 weeks.14-16 Many 
factors like age, female gender, diabetes, hypertension, 
vessel diameter and hematological factors affect this process 
and can result in AVF failure.16,17,11 In our study we 
specifically concentrated on association of inflammatory 
biomarker 
Many studies suggest that inflammation causes intimal 
hyperplasia and higher chances of thrombosis at anastomotic 
site and hence responsible for failure of AVF.11,12 Hence 
measuring inflammatory markers like CRP can point out 
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those patients who are at a higher risk of AVF maturation 
failure. Wong et al found for the first time that aggressive 
intimal hyperplasia at anastomotic site is associated with 
thrombotic closure of AVF thus pointing out inflammation 
as a culprit for higher AVF failure.11 Neutrophil-lymphocyte 
ratio (NLR) is also a marker of systemic inflammation and is 
also used by certain studies as a benchmark to assess the 
association between inflammation and failure of fistula. 
Yilmaz et al in his logistic regression model has recently 
advocated that NLR is an independent positive predictor of 
AVF failure.18 
Similar inference was also deducted by Roy-Chaudhury et al 
who found a strong positive association between 
inflammatory cell markers like CRP and fibrinogen, and 
failure of vascular access.19 Chou et al suggested that 
elevated CRP is strong positive predictor for AVF 
thrombosis and they have found it as an independent risk 
factor for AVF failure.12 Our study also shows that patients 
who had a higher levels of inflammation as evident from 
elevated CRP had higher rates of AVF failure. Kaygin et al 
in their study of 213 patients also found that high CRP levels 
in their patients who had failed AVF had significant 
impact.20 A p-value of less than 0.001 was strongly 
suggestive of statistically significant effect of raised CRP on 
the fistulae failure rate. We have also found similar effect of 
raised CRP with a p-value of 0.003. 
However, certain studies suggest that there is no relation of 
CRP levels and AVF failure. Meta-analysis by Morton et al 
in 2016 suggested that the current inflammatory biomarkers 
available are yet to identify the fistulas which are at risk.21 
Hence they have suggested that more robust biomarkers are 
needed which can predict the fistula failure rate. Similarly, 
Choice for Healthy Outcome In Caring for End stage renal 
disease (CHOICE) study by Banerjee et-al in 2010 reported 
higher failure of catheter related vascular access in patients 
with elevated CRP, however they did not find higher failure 
rates of AVF in patients with raised CRP levels.22  
Low level of hemoglobin (Hb) is also thought to cause low 
grade inflammation and hence some workers have also 
labeled low Hb as a positive predictor for higher failure 
rates of AVF.23,24 Hence those ESRD patients who have 
anemia may also be at a higher risk for failed AVF and 
probably CRP can be used as a marker to predict failure in 
such cases. We did not assess the Hb level and its 
association with CRP and AVF failure rate in this study. 
 
Conclusion 
Inflammation has a definite role in failure of AVF. 
Measurement of inflammatory markers like CRP can help in 
identifying those patients who are at high risk of access 
failure. We recommend further studies with larger sample 
size to define the exact role of inflammatory biomarkers. 
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